South America Melanoma Diagnostics and Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The South America melanoma diagnostics and therapeutics market size was valued at USD 0.46 billion in 2025 and is estimated to grow from USD 0.51 billion in 2026 to reach USD 0.89 billion by 2031, at a CAGR of 11.67% during the forecast period (2026-2031). This report is segmented by Product Type (Diagnostics, Therapeutics), Route of Administration (Intravenous, Oral, Subcutaneous, Local/Topical), End User (Hospitals and Oncology Centers, Diagnostic Labs, Specialty Clinics, Academic Institutes), and Geography (Brazil, Argentina, Colombia, Chile, Peru, Rest of South America). The Market Forecasts are Provided in Terms of Value (USD).

South America Melanoma Diagnostics and Therapeutics Market Trends and Insights

Expanding Immunotherapy and Targeted Therapy Adoption Transforms Therapeutic Mix

The shift from dacarbazine-based chemotherapy to immune checkpoint therapies is reshaping treatment demand across the South America melanoma diagnostics and therapeutics market. A Brazilian private oncology network reported a median overall survival of 34 months among 723 patients with metastatic melanoma who received first-line immune checkpoint inhibitor therapy.Combination therapies have increased demand for biomarker-guided treatment selection, including BRAF, NRAS, PD-L1, and tumor mutational burden testing. Targeted BRAF and MEK inhibitor combinations remain important for BRAF-mutated disease, supporting demand for oral treatment options. Integrated pathology, molecular testing, and medicine access strengthen care delivery and market access.

Public Sector Anti-PD-1 Incorporation Widens Access, with Structural Constraints

Brazil incorporated nivolumab and pembrolizumab for advanced melanoma into the Unified Health System (SUS) in August 2024, establishing a formal public access pathway. However, only 15.8% of melanoma treatment authorizations included these medicines during the first four years after incorporation. In March 2026, Brazil’s Ministry of Health, MSD, and Instituto Butantan established a Productive Development Partnership for 10 years of domestic pembrolizumab technology transfer. Colombia also covers BRAF PCR testing through its national healthcare system, with each test valued at USD 300. Procurement budgets and pharmacovigilance requirements continue to affect the pace of therapy adoption.

High Cost and Budget Impact of Advanced Therapies Limits Public Uptake

The high cost of advanced melanoma therapies limits adoption across public healthcare systems. A Brazilian budget impact analysis projected that increasing nivolumab and pembrolizumab penetration to 80% over five years would require additional spending of BRL 564 million (USD 108.98 million). The analysis also identified a 583% increase in per-authorization costs for concurrent nonbiologic medicines. Fiscal constraints in Argentina, Colombia, Peru, and Brazil can delay reimbursement decisions, disrupt procurement continuity, and restrict patient access despite regulatory approval. Consequently, market growth in public settings may remain below the level indicated by disease burden.

Other drivers and restraints analyzed in the detailed report include:

• Rising Melanoma Incidence and Referral Capacity Create Uneven Demand
• Advancing Molecular and Digital Pathology Strengthens the Diagnostic Base
• Uneven Access to Dermatology, Biopsy, and Oncology Services Limits Realized Potential

Segment Analysis

Therapeutics accounted for 73.21% of the South America melanoma diagnostics and therapeutics market share in 2025, supported by high spending on immune checkpoint inhibitors and longer treatment cycles. Between 28% and 36% of patients in South America presented with stage III or IV disease, driving demand for systemic treatment. Anti-PD-1 regimens and combination protocols replaced chemotherapy as the preferred first-line option for eligible patients. BRAF and MEK inhibitor combinations served patients with BRAF-mutated melanoma, with prevalence ranging from 47% to 53% among advanced cutaneous melanoma patients in Brazil and Chile.

Diagnostics is forecast to grow at a CAGR of 12.67% from 2026 to 2031, making it the faster-growing product category. Biopsy, dermatoscopy, molecular panels, and pathology services support treatment eligibility. The 2025 Brazilian pathology guidelines expanded the role of structured biopsy assessment, BRAF testing, and sentinel-node reporting. Brazil added 1,500 to 2,000 board-certified dermatologists between 2020 and 2025, supporting greater device utilization and earlier biopsy referrals. The Latin American Digital Pathology Association launched in November 2025 to advance whole-slide imaging, AI-assisted diagnostics, and cloud-based collaboration. Argentina and Colombia are beginning to adopt models used in Brazil’s metropolitan oncology centers.

Complete Report Scope:

• By Product Type
  • Diagnostics
    • Dermatoscopy Devices
    • Biopsy Devices
  • Therapeutics
    • Chemotherapy
    • Biological Therapy
    • Targeted Therapy
    • Immune Therapy
• By Route of Administration
  • Intravenous
  • Oral
  • Subcutaneous
  • Local and Topical Routes
• By End User
  • Hospitals and Oncology Centers
  • Diagnostic Laboratories
  • Specialty Clinics and Dermatology Practices
  • Academic and Research Institutes
• By Geography
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America

List of Companies Covered in this Report:

• A.C. Camargo Cancer Center
• Abbott Laboratories
• Agilent Technologies
• Amgen
• Beckton Dickinson
• bioMérieux
• Bristol-Myers Squibb
• Danaher
• Diagnosticos da America S.A.
• Roche
• GlaxoSmithKline
• Grupo Fleury S.A.
• Hospital Israelita Albert Einstein
• Illumina
• Merck
• Novartis
• Pfizer
• QIAGEN
• Siemens Healthineers
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support